3-D Matrix, Inc., based in Waltham, Massachusetts, is a wholly owned subsidiary of 3-D Matrix, Ltd., Tokyo, Japan. The 3-D Matrix Group develops and manufactures a family of peptide biomaterials under the trade name PuraMatrix® for use in clinical applications and life science research.
3-D Matrix has driven development of its technology using a “lean company” model, leveraging the activities of its founding scientists at MIT, the company’s multiple collaborations with leading companies, outsourced manufacturing to contract facilities, and distribution agreements for its commercial products. This structure has proven extremely efficient at driving pre-clinical proof-of-concept studies while commercializing products with the life science and drug discovery research communities. The company intends to build its business development and scientific staff to mirror the near-term opportunities driven by partnerships as well as internal developments.
Keiji Nagano started his business career at Exxon Mobil before moving to Bain & Co. where he lead the Tokyo Branch as Vice President. He also headed the company’s Korean Branch for its first four years. During his years at Bain & Co., Mr. Nagano and his team worked on various projects in biotech, health care, IT, new technology, financial and entertainment businesses, and also helped successfully bring in foreign operations to the Japanese market. In 2004, he established 3-D Matrix, Ltd., and introduced PuraMatrix® in Japan. 3-D Matrix, Ltd. is the parent company of 3-D Matrix Inc.